The postacrosomal sheath (PAS) of the perinuclear theca (PT) is the first compartment of the sperm head to solubilize into the ooplasm upon sperm-oocyte fusion, implicating its constituents in zygotic development. This study investigates the role of one such constituent, glutathione-Stransferase omega 2 (GSTO2), an oxidative-reductive enzyme found in the PAS and perforatorial regions of the PT. GSTO2 uses the conjugation of reduced glutathione, an electron donor shown to be compulsory in sperm disassembly within the ooplasm. The proximity of GSTO2 to the condensed sperm nucleus led us to hypothesize that this enzyme may facilitate nuclear decondensation by reducing disulfide bonds before the recruitment of GSTO enzymes from within the ooplasm. To test this hypothesis, we utilized a cell permeable isozyme-specific inhibitor, which fluoresces when bound to the active site of GSTO2, to functionally inhibit spermatozoa before performing intracytoplasmic sperm injections (ICSI) in mice. The technique allowed for targeted inhibition of solely PT-residing GSTO2, as all that is required for complete zygotic development is the injection of the mouse spermatozoon head. ICSI showed that inhibition of PT-anchored GSTO2 caused a delay in sperm nuclear decondensation, and further resulted in untimely embryo cleavage, and an increase in fragmentation beginning at the morula stage. The confounding effects of these developmental delays ultimately resulted in decreased blastocyst formation. This study implicates PT-anchored GSTO2 as an important facilitator of nuclear decondensation and reinforces the notion that the PAS-PT is a critical sperm compartment harboring molecules that facilitate zygotic development. 
Introduction
In mammalian spermatozoa, the nucleus is encapsulated by the perinuclear theca (PT), a dense detergent-resistant cytosolic protein layer that acts as a key cytoskeletal component of the head [1] [2] [3] [4] [5] [6] [7] [8] . In spatulate spermatozoa, the PT can be functionally and developmentally divided into two regions: the subacrosomal layer (SAL) and the postacrosomal sheath (PAS), whereas in falciform murid spermatozoa, a third region of the PT is present called the perforatorium (Figure 1 ). The perforatorium is an extension of the PT that surrounds the extreme apical region of the nucleus and extends anteriorly to form the hook-like protrusion that give falciform spermatozoa their characteristic shape [9] [10] [11] [12] [13] [14] [15] . The SAL underlies the acrosome and has been implicated in acrosome vesicle transport and attachment to the spermatid nucleus during the early steps of spermiogenesis [1, 16] . Conversely, the PAS is the continuation of the PT that forms just below the acrosome and proceeds distally, enveloping the caudal aspect of the spermatozoon nucleus with the exception of the tail implantation fossa. Formed during the elongation phase of spermiogenesis, the PAS is a densely packed cytosolic protein capsule that has been shown to house proteins involved in the fertilization process [1, 9, [17] [18] [19] [20] . The PAS is also the first sperm head component to solubilize within the ooplasm [1, 21] supporting Figure 1 . A mid-sagittal section of a mouse sperm head with the acrosome superimposed. The apical region of the nucleus (black) is covered by the subacrosomal layer (SAL, dark blue), a proteinaceous layer between the nuclear envelope and the inner acrosomal membrane. The caudal region of the nucleus is enclosed in the postacrosomal sheath (PAS, bright green) and is composed of predominantly insoluble cytosolic proteins. The unique perforatorial structure (dark green) found in falciform spermatozoa is an electron dense structure that invades the space between the SAL and the nuclear envelope at the apical region of the nucleus, and extends outward to form the characteristic hook shape found in most murids.
the proposed functionality of its residents as participants in early zygotic development. In murids, the functionality of the perforatorial region of the PT has yet to be elucidated, but has been shown to house our protein of interest, glutathione-S-transferase omega 2 (GSTO2), in addition to the PAS [9, 15] .
GSTO2 is one of only two known functional enzymes within the omega class of the glutathione-S-transferase (GST) superfamily [22] . This group of phase II detoxification enzymes function through the conjugation of glutathione, a tripeptide thiol, with the electrophilic centers of substrates to facilitate reduction reactions. In addition to the glutathione reductase functionality possessed by all GST enzymes, the Omega class have also been suggested to facilitate glutathione-dependent dehydroascorbate reductase and thiolation reactions [23] [24] [25] . The increased diversity of enzymatic reactions facilitated by GSTO enzymes may be attributed to their active site, which shares structural homogeny with thioredoxins and glutaredoxins, and houses a cysteine residue, as opposed to the serine or tyrosine present in all other GST enzymes [24] [25] [26] .
The oxidative-reductive power that facilitates all GST functionality comes primarily from its conjugate thiol, glutathione (GSH). Thiols act as a natural reservoir of reducing power within the cell, facilitating detoxification and protection against oxidative stress. In maturing oocytes, glutathione has been shown to be a vital constituent of the ooplasm, and is a suggested marker of oocyte maturation [27] [28] [29] [30] [31] [32] [33] . Once oocytes are mature, GSH becomes an active constituent of the ooplasm and participates in processes such as shaping of the meiotic spindle [34] . Moreover, in the newly fertilized oocyte, the use of GSH as an oxidative-reductive substrate facilitates chromatin decondensation and pronuclear formation, which are essential steps in early zygotic development [29, [35] [36] [37] [38] . The large demand for GSH conjugation during this time leads to a dramatic decrease in the GSH stores that have accumulated during oogenesis [39] . Therefore, the aforementioned evidence supports a pivotal role for GSH during nuclear reorganization at/after fertilization.
The ability of the mammalian sperm head to decompartmentalize and commence nuclear decondensation within the ooplasm has been shown to depend at least partially on the reduction of disulfide bonds and the availability of GSH [35, 40, 41] . In multiple in vitro studies performed in rabbit, glutathione reductase activity has been implicated as a key factor in this process [40, 41] . Past findings have also suggested that this process is enzymatic in nature and that nuclear decondensation begins in the PAS region and proceeds apically [41] . Therefore, we postulate that mammalian spermatozoa utilize spermborne GSTO2, found within the PT, during sperm head decompartmentalization and paternal pronuclear (PN) development immediately after fertilization and before the recruitment of oocyte-residing GSTO enzymes. This pre-packaging of an oxidative-reductive enzyme within the PT would allow for a more efficient breakdown of the spermatozoon head and facilitate the timely onset of male nuclear decondensation. Through intracytoplasmic sperm injection (ICSI) and functional inhibition studies, we sought to define the functional role of sperm-borne, PT-anchored GSTO2 with respect to spermatozoon decompartmentalization and nuclear decondensation. Our findings demonstrate the novel role of PT-anchored GSTO2 in sperm nuclear decondensation and show the interplay of sperm-borne and oocyte-borne GSTO enzymes in early zygotic development.
Methods and materials

Animals
Mice were purchased from Charles River Laboratories (Charles River, St-Constant, QC, Canada). All procedures in this study were conducted under Animal Utilization Protocols approved by Queen's University and Université de Montreal Animal Care Committees and complied with the Guidelines of Canada Council on Animal Care.
Sperm collection
Spermatozoa were obtained from the fresh cauda epididymides of mature CD-1 male mice. The epididymides were placed in 1ml trisbuffered saline (TBS) (pH 7.5-8) solution. The spermatozoa were collected in TBS solution by piercing and gently squeezing the epididymides so that the spermatozoa diffused into the solution. The sperm-containing suspension was aliquoted and washed by centrifugation in TBS twice at 1000g for 5 min. The sperm pellets were either used immediately or frozen at −80˚C until needed.
Antibodies
The central antibody was a goat polyclonal anti-GSTO2 (Y-12) (Santa Cruz) that was used at a 1:1000 concentration for Western blot analysis and 1:30 concentration for fluorescent immunocytochemistry. For Western blot analysis, the secondary antibody used was rabbit anti-goat IgG-HRP (horseradish peroxidase) (Santa Cruz, 1:10,000), whereas for immunofluorescence, donkey anti-goat IgG-CFL (colorized fluorochrome) 555 was used (Santa Cruz, 1:100). A membrane permeable cell tracker probe (Invitrogen Molecular Probes C7025, Waltham, Massachusetts, USA), that binds covalently and irreversibly to the active site of GSTO isozymes [42] was used as an inhibitor of GSTO enzymes at a concentration of 100 μM.
Fluorescent electrophoresis and western blotting analysis
Sperm samples were incubated for 40 min at 37
• C with a fluorescent probe (C7025) that binds to the active site of GSTO enzymes and washed twice. Samples were solubilized in reducing sample buffer (200 mM Tris 6.8, 4% SDS, 0.1% bromophenol blue, 40% glycerol, 5% β-mercaptoethanol) and 5-10 million spermatozoa were loaded per lane and resolved on a 4% stacking and 12% separating polyacrylamide gel as described by Laemmli [43] , along with a BLUeye pre-stained protein ladder (GeneDirex). The gel was run at 100 volts for 110 min, subsequently placed in transfer buffer and imaged in a fluorescent biophotonic chamber. The proteins were then transferred onto a polyvinylidene fluoride membrane (Millipore) for 120 min in Tris-glycine transfer buffer on ice using a Hoefer Transphor apparatus (Hoefer Scientific Instruments). The membrane was also imaged in the fluorescent biophotonic chamber before it was blocked with 10% skim milk in phosphate-buffered saline (PBS) with 0.05% Tween-20 (PBS-T) and incubated for 30 min to avoid nonspecific binding. The membrane was then incubated with primary antibody overnight at 4˚C. The membrane was washed six times in PBS-T for 5 min each, followed by incubation in secondary antibody conjugated to HRP for 2 h. The membrane was again washed extensively before the immunodetection reaction was visualized using Clarity TM Western ECL Substrate (Bio Rad Laboratories). The membrane was exposed to X-ray film for developing.
Immunofluorescence
Mouse spermatozoa were mounted on poly-L lysine coated coverslips and fixed in 2% formaldehyde in PBS for 40 min at room temperature, before permeabilization in PBS with 0.1% Triton-X-100 (PBS-Tx) for an additional 40 min. The cells were blocked with 5% bovine serum albumin (BSA) in PBS-Tx for 25 min to avoid nonspecific binding, and incubated with primary antibody overnight at 4˚C. Next, the cells were washed in 1% BSA-PBS-Tx and incubated in secondary antibody conjugated to a fluorescent marker for 40 min at room temperature, shielded from light. The secondary antibody mixture included the blue-fluorescent DNA-stain DAPI (4 , 6-Diamidino-2-Phenylindole). The coverslips were mounted onto glass slides using VectaShield mounting media (VectorLabs, Birmingham) and sealed with nail polish. Images were captured at the Queen's University Cancer Biology Institute Imaging Centre, using a Quorum Wave Effects spinning disc confocal microscope.
Mouse gamete preparation, microinjection and analysis
Mouse cauda epididymides were isolated from adult BLK-6 males and punctured with a 26G needle to allow spermatozoa to swim out into EmbryoMax human tubal fluid medium (Millipore, MR-070-D). In each replicate, spermatozoa from one male were used for all treatments, to avoid any variance between animals. Spermatozoa were divided into treatment groups once they had evenly dispersed out of the epididymis. For the treatment groups, the GSTO2-inhibited spermatozoa and vehicle control spermatozoa were pre-incubated with the inhibitor (C7025, 100 μM) or equivalent volume of DMSO, respectively, for 40 min at 37
• C and 5% CO 2 before use. Untreated control spermatozoa were kept at 37
• C and 5% CO 2 until needed. For each replicate, four 8-week-old CD-1, or B6D2F1 females were super-ovulated by intraperitoneal injection of 10 IU pregnant mare serum gonadotropin (Sigma) followed 48 h later with 10 IU human chorionic gonadotropin (hCG) (Sigma). Oocytes were collected from oviducts into M-2 medium (Millipore, MR-015-D) 13 h after hCG injection and cumulus oophorus cells removed by treatment with 0.1% hyaluronidase in M-2. The cumulus-free oocytes were washed in M2. Untreated and treated oocytes were left to rest in KSOM (Millipore, MR-020P-5F) media under mineral oil in an incubator set to 37
• C and 5% CO 2 before injection. For treatment groups requiring oocyte GSTO inhibition, oocytes were incubated with the inhibitor (C7025, 50 μM) for 40 min before being washed and injected. Micromanipulation and ICSI were performed according to standard protocols on the stage of a Nikon Ti-S inverted microscope (Nikon Canada Inc., Mississauga, ON, Canada) fitted with Narishige micromanipulators (Narishige International US Inc., Amityville NY, USA) and Piezo PMM-150HJ/FU drill (Prime Tech Ltd, Ibaraki, Japan). Sperm heads and tails were separated at the head-tail junction using the piezo drill and the heads of treatment group sperm were washed twice before injection into MII arrested oocytes. Post-injection, oocytes were incubated in KSOM media at 37 Figure 2. Mouse GSTO sequence comparison. The mouse glutathione-s-transferase omega 2 (mGSTO2) and glutathione-s-transferase omega 1 (mGSTO1) protein sequence alignment. The active site cysteine (aa32) in both protein sequences is bolded and the inhibitor (CellTracker C7025) binding site is highlighted in green. Fully conserved residues within the binding sites are indicated by an asterisk ( * ), residues with strong similarity are indicated by a colon (: ) and weakly similar residues are indicated by a period (.). The inhibitor is a membrane permeable probe that covalently binds to the active site and fluoresces when bound.
in 2% formaldehyde, stained with DAPI (0.3 mg/ml) and imaged using a Quorum Wave Effects Spinning Disc Confocal microscope.
Statistical analysis
Statistical significance was determined based on an unpaired t-test with Welch's Correction, a one-way ANOVA.
Results
To test whether the PT-anchored GSTO2 in spermatozoa is essential for normal zygotic development, we acquired an isozyme-specific inhibitor that specifically inhibits the activity of GSTO1 [42] . This inhibitor (C7025, ThermoFisher Scientific) is cell permeable, fluorescent when substrate-bound and inhibitory to the active site of GSTO1. The molecule has been shown to form a non-reversible covalent bond within the active site of GSTO1 and is believed to interact with the Cys32 residue of the catalytic site in conjunction with GSH, located within its G-site, when the enzyme is in its functional conformation [42] . Due to the high sequence homology between GSTO1 and GSTO2 (Figure 2 ), C7025 was tested to determine if it could specifically bind to GSTO2 in spermatozoa. Fluorescent gel electrophoresis of the isolated sperm heads confirmed binding specificity of the inhibitor (C7025) at 28 kDa, the molecular mass associated with the prominent GSTO2 isoform ( Figure 3A, lane 1) . When the inhibitor-bound fluorescent band was transferred to a membrane ( Figure 3A , lane 2) and probed with an anti-GSTO2 (Y-12) antibody, there was only one immunoreactive band at 28 kDa ( Figure 3A , lane 3), validating specificity. To lend further support to these findings, the heads of mouse spermatozoa were incubated with the fluorescent inhibitor C7025 and imaged using fluorescent microscopy. The inhibitor localized to the PAS and perforatorial regions of the PT, the same localization seen with fluorescent immunocytochemistry using the anti-GSTO2 (Y-12) antibody ( Figure 3B ).
To investigate the implications of the functional inhibition of sperm-borne GSTO2 enzymes, ICSI studies were performed in mice. For fertilization to be successful, the mouse oocyte requires only the sperm head to be injected into the ooplasm, ensuring the effects seen are exclusive to the inhibition of PT-anchored GSTO2, and eliminating potential interference by GSTO enzymes that may be localized within the sperm tail structures or on the plasmalemma. Treated spermatozoa were pre-incubated with the inhibitor or vehicle (DMSO) for 40 min prior to injection into MII arrested oocytes. Fertilized oocytes were observed at four stages of development: Sperm nuclear decondensation within the ooplasm was investigated 2.5 h post-injection and the nuclei/paternal PN were categorized into one of five stages of decondensation according to a previous report [44] . Our findings showed a negative developmental shift and a statistically significant difference in sperm nuclear transformation between the sperm-borne GSTO2-inhibited, oocyteborne GSTO-inhibited and control groups (Figure 4) . The spermborne GSTO2 inhibition group had approximately 70% of the observed sperm nuclei within the ova in stages 1 and 2 ( Figure 4a) . The oocyte-inhibited GSTO group presented with 95% of observed sperm nuclei within the ova in stage 1, and the remaining 5% of The cleavage rates of control (ICSI Control), DMSO-treated spermatozoa (Vehicle Control), sperm-borne GSTO2-inhibited (Sperm Inhibited), and oocyteborne GSTO-inhibited (Oocyte Inhibited) groups during mouse ICSI. Cleavage was investigated 24 h after standard mouse ICSI procedures. Three replicates were completed per group. In both the ICSI control and vehicle control, at least 83% of zygotes successfully cleaved, whereas only 18% of the sperm-inhibited, and none of the oocyte-inhibited zygotes had successfully transitioned to the two-cell stage. Representative DAPI stained images of each group are found directly below the graph. Statistical significance was determined based on an ANOVA and letters (a, b, c) indicate a significant difference at P < 0.001. Error bars denote standard error of the mean between trials. sperm nuclei presented in stage 2 (Figure 4a ). These results are in contrast to the ICSI control group that showed approximately 70% of the sperm nuclei/paternal PN in stages 3-5 ( Figure 4a ). The average stage of sperm nuclear decondensation achieved in each group was assessed to determine the statistical significance of the delay accrued within each of the treatment groups. While ICSI control ova showed an average sperm nuclear decondensation progression to stage 3.5 of the 5-stage process, the average progressions of the sperm-borne GSTO2-inhibited and the oocyte-borne GSTO-inhibited groups were only to stages 2.2 and 1.1 respectively (Figure 4b) .
The developmental delay observed in nuclear decondensation/PN development persisted throughout early zygotic development and resulted in a statistically significant delay in reaching first cleavage at 24 h post-injection. Only 19% of sperm-borne GSTO2 inhibited ova were able to successfully cleave, compared to 86% of the ICSI control group. Additionally, when the effects of oocyte-borne GSTO inhibition were examined at this 24 h time point, the sperm nuclei remained in the early stages of decondensation and no ova were able to cleave ( Figure 5 ). This suggests that the GSTO family of enzymes (GSTO1 and GSTO2) residing in the oocyte also play an essential role in regulating the oxidative-reductive environment during nuclear decondensation and early zygotic development.
To investigate the capacity of mouse zygotes to recover from delays acquired during nuclear decondensation, embryos were observed 48 h post-sperm injection. The GSTO2-inhibited spermatozoa group displayed a persistent and statistically significant developmental delay, with only 28% of the embryos successfully progressing to the 4-cell stage compared to 66% of the ICSI control embryos (Figure 6a ). This developmental delay translates to a median embryonic cell number of 2 and an average embryonic cell number of only 2.5 within the sperm-borne GSTO2-inhibited group, compared to a median embryonic cell number of 4 and an average embryonic cell number of 3.2 within the ICSI control group (Figure 6b) .
Lastly, to determine the viability of embryos within the spermborne GSTO2-inhibited group, embryos were cultured for 96 h to investigate their ability to develop to blastocyst. The successful blastocyst development of the sperm-borne GSTO2-inhibited group was significantly lower than the ICSI control group, with only 36% progressing to at least the early blastocyst stage by 96 hours, compared to the ICSI control group which saw 78% of embryos reaching early blastocyst or beyond (Figure 7b) . The greatest proportion of embryos within the sperm-borne GSTO2-inhibited group remained within the morula stage, but a subset was also observed to be more severely delayed, failing to reach compaction, characteristic of morula development (Figure 7a) . Overall, there was also a significant increase in fragmentation and cell death within the sperm-borne GSTO2-inhibited group, with 27% of embryos fragmenting or dying before 96 h compared to the 4% of the ICSI control embryos that fragmented or died within the same time frame (Figure 7c ).
Discussion
Through the use of an inhibitor with the capability to selectively inhibit GSTO2 within the confines of the sperm head PT, we were able to study the impact of its functional absence post-fertilization. Our results suggest that sperm-borne GSTO2 plays a significant role in sperm nuclear decondensation and paternal PN development by Figure 7 . The distribution of developmental progression in embryos injected with untreated spermatozoa (ICSI Control, n = 101) and embryos injected with spermborne GSTO2-inhibited spermatozoa (Sperm Inhibited, n = 134) using mouse ICSI cultured to 96 h. Development was investigated in embryos fixed at 96 h post injection and stained with DAPI to examine chromatin appearance. Embryos were stratified based on their morphology to determine developmental progression. (A) At the 96 h time point, all the control embryos had progressed to at least the morula stage and the majority (78%) had commenced blastocyst formation. In contrast, the sperm-borne GSTO2-inhibited group had a more varied developmental distribution. A small subset of embryos were in the developmental stages before cell compaction (12%), approximately a fourth of embryos were still within the compacted morula stage (24%) and only 36% of embryos successfully reached blastocyst formation. (B) The precentage of blastocyst formation at 96 h post injection within the ICSI control and sperm-borne GSTO2-inhibited groups. (C) The level of cell death at 96 h post-injection within the ICSI control and sperm-borne GSTO2-inhibited groups. The bars represent the averages from three trials and the error bars depict the standard error of the mean between trials. There was a statistically significant difference in blastocyst development and cell death between the ICSI control group and the sperm-borne GSTO2-inhibited treatment group (P < 0.05). The statistical significance was determined based on an unpaired t-test and is depicted on the graph by the letters (a, b).
increasing the efficiency of this process during sperm decompartmentalization in the ooplasm. Delays accrued early in development by the inhibition of sperm-borne GSTO2 does not appear to be fully rescued by oocyte-borne GSTOs. Thus, the interplay between GSTOs residing within the spermatozoon and the oocyte appear to be crucial in facilitating timely and complete sperm nuclear decondensation during early zygotic development.
As a member of the GST superfamily, GSTO2 uses glutathione to catalyze oxidative and reductive reactions through the use of the electrophilic centers of substrates. Past studies have shown the importance of glutathione in oxidative-reductive reactions taking place during fertilization such as nuclear decondensation and the correct positioning of the sperm aster [33] , but the enzymes needed to drive these reactions have yet to be identified.
Our findings suggest that GSTO2, packaged within the PAS and perforatorial regions of the PT in mouse spermatozoa, is utilized during sperm nuclear decondensation and sperm head decompartmentalization whilst oocyte-borne enzymes are recruited. The prepackaging of an oxidative-reductive enzyme within the sperm head itself would ensure the most efficient breakdown of the spermatozoon components after sperm-oocyte fusion. This would allow for the acceleration of disulfide bond disassembly within the sperm head, including solubilization of the PAS constituents immediately after sperm entry into the ooplasm. The additional localization of GSTO2 within the perforatorial region of the PT in murids may also aid in providing a continuous supply of the enzyme as the sperm head PT continues to break down rostrally. The quick degradation of cytoskeletal components in the sperm head and immediately surrounding the nucleus may also allow for a more efficient nuclear decondensation, by facilitating a greater infiltration by ooplasmic enzymes, nuclear/chromatin components and reducing agents such as GSH. The increased availability of GSH from the ooplasm may also help facilitate the enzymatic activity of previously reported glutathione dependent nuclear matrix proteins that have been implicated in male nuclear decondensation such as glutathione peroxidase 4 and peroxiredoxin 6 [45, 46] . Ultimately, the activity of GSTO2 may facilitate the early interactions between sperm-and oocyteborne enzymes and substrates required for efficient sperm nuclear decondensation. Through inhibiting sperm-borne GSTO2 enzymes prior to fertilization, we were able to show a significant change in the rate of developmental progression at four distinct time points of zygotic and embryonic development (sperm nuclear decondensation/PN development, first embryonic cleavage, second embryonic cleavage and blastocyst formation).
The developmental delay at 2.5 h post-injection in mouse ICSI implies that sperm-borne GSTO2 and oocyte-borne GSTO enzymes are active participants in the facilitation of sperm nuclear decondensation. Furthermore, these findings reinforce the hypothesis that the sperm PT contains molecules that are essential to the fertilization process. To assess if the early delay in sperm head remodeling and nuclear decondensation influences the ability of the oocyte to reach the developmental checkpoint of the first embryonic cleavage, zygotes were observed 24 h post-injection. Although a small subset of ova successfully cleaved at the expected timepoint (19%), the majority of ova injected with sperm-borne GSTO2-inhibited spermatozoa remained at the 1-cell stage. The 1-cell ova did show successful formation of two pronuclei at the 24 h timepoint but showed no indication of cleavage. In contrast, when GSTO enzymes within the ooplasm were inhibited and observed 24 h post-injection, there was no successful cleavage and all ova still had sperm heads in the early stages of nuclear decondensation. Together, these findings suggest the GSTO enzymes present within the sperm head and the ooplasm have distinct but intertwined roles in ensuring the successful completion of male nuclear decondensation and timely zygotic development. The developmental delay in nuclear decondensation of the PT-anchored GSTO2-inhibited spermatozoa persisted through the 4-cell cleavage stage and into blastocyst formation. The increase in cell death and fragmentation observed within the sperm-borne GSTO2-inhibited group at 96 h also suggests a large subset of embryos experienced developmental complications as a result of sperm-borne GSTO2 inhibition, adding support to the importance of sperm-borne GSTO2 in the early male nuclear transition.
Whilst the inhibition of sperm-borne GSTO2 before fertilization did result in the majority of fertilized embryos accruing developmental delays, a small subset consistently maintained the expected developmental progression. The dense compaction of the PAS and perforatorial regions of the PT may have led to an inaccessibility of some GSTO2 enzymes and therefore the overall inhibition of GSTO2 in injected spermatozoa may have varied. Consequently, while the current study demonstrates the novel involvement of PT-derived GSTO2 in the nuclear decondensation process, it may underplay the true measure of its influence.
This study reinforces the importance of oxidative-reductive reactions during early embryogenesis. Recent work in Drosophila has highlighted the critical role of the oocyte-specific thiroedoxin gene deadhead (DHD) within the paternal nuclear transition and formation of the male pronucleus [47] [48] [49] [50] [51] . However, this DHD dependent ROS scavenger system is not evolutionarily conserved in mammals. Therefore, it is proposed that the GSTO enzymes within both the sperm and oocyte in coordination with GSH may take over this redox control of paternal nuclear transition in mammals.
Our investigation shows one of the first instances of a spermborne PAS and perforatorial constituent playing a significant role post-activation, within the developing zygote. We demonstrate that PT-anchored GSTO2 actively participates in sperm nuclear decondensation, most likely facilitated by the reducing power of glutathione. Lastly, these findings support our hypothesis [1] that spermatozoa pre-package proteins within regions of the PT that are essential for fertilization.
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